Abstract:This article reviews resistance to chemotherapy in metastatic castration-resistant prostate cancer (CRPC), which is a result of mechanisms of resistance specific to prostate cancer and to general mechanisms common to different cancer types. New therapies targeting these mechanisms are outlined and their potential impact in future and ongoing clinical trials is discussed. Knowledge of the mechanisms of drug resistance offers great hope for future effective therapy; however, drug resistance in metastatic CRPC is multifactorial and complex and the development of new medical therapies remains challenging.

Drug resistance in metastatic castration-resistant prostate cancer